[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myomectomy-surgical-blood-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myomectomy-surgical-blood-loss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100620064","bilateral-uterine-artery-occlusion-during-laparoscopic-myomectomy-100620064",false,"NCT07352761","Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy","Comparing Different Techniques of Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* women with uterine fibroids and complaining of either abnormal uterine bleeding, infertility, urinary or rectosigmoid pressure manifestations.\n* Fibroid size from 3 - 10 cm in diameter and with\n* a maximum number of 3 fibroids.\n\nExclusion Criteria:\n\n* contraindication to pneumoperitoneum and laparoscopy,\n* patients with BMI \\> 30 kg\u002Fm2,\n* history of midline abdominal incisions,\n* women with history of prior ovarian surgery,\n* women with history of hormonal treatment for the last 3 months before surgery,\n* women who are not good candidate for myomectomy and who would benefit more from hysterectomy such as, women with multiple ≥ 4 leiomyomata, associated adenomyosis, recurrent fibroids after myomectomy.\n* suspected endometrial malignancy or suspected leiomyosarcoma features on ultrasound and\u002For MRI.\n* Submucous fibroids who will undergo hysteroscopic myomectomy beside the laparoscopic surgery.","FEMALE",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","The current study is a multiple-arm, single blinded, and controlled randomized trial. It will be conducted in two gynecological endoscopy centers: • ElShatby University Hospital, a tertiary level hospital in Alexandria, Egypt. • Al-Madina Women Hospital, A specialized hospital of Obstetrics and Gynecology, Alexandria, Egypt. Patient selection: women with uterine leiomyomata and planning for laparoscopic myomectomy will be assessed for eligibility then will be enrolled in the trial according to the following inclusion and exclusion criteria, after providing a written informed consent of participation. Outcome variables of the study: The primary outcome is intraoperative blood loss and the change in postoperative hemoglobin. The secondary outcomes of this study are the operative time of performing uterine arteries occlusion and the postoperative ovarian reserve.",[25,26,27],"Uterine Fibroids (Leiomyoma)","Myomectomy","Myomectomy; Surgical Blood Loss",[29,30,31,32,33],"Fibroids","Laparoscopic myomectomy","Blood loss","Uterine artery occlusion","Ovarian reserve","RECRUITING","2026-01-13",{"date":37,"type":38},"2026-01-20","ACTUAL",{"date":40,"type":38},"2025-05-01",{"date":42,"type":19},"2026-02-28",{"name":44,"class":45},"Alexandria University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100583937","prevention-of-hemorhagic-risk-in-upper-myomectomy-by-use-of-misoprostol-100583937","NCT06882824","Prevention of HEMOrhagic Risk in Upper MYOmeCTomy by Use of Misoprostol.","HEMOMYOC","Inclusion Criteria:\n\n* Patient aged 18 to 43\n* Symptomatic myomas (bleeding, pain or infertility)\n* Indication for laparoscopic myomectomy Fibroma ≤ 10cm or number ≤ to 4 fibroids\n* Indication for myomectomy by laparotomy Fibroma \\> 10cm, Number \\> to 4 fibroids\n* OTAU possible intraoperatively (Clip on uterine artery and tourniquet placement)\n* Speak and understand French\n* Affiliated with a social security scheme.\n\nExclusion Criteria:\n\n* History of major uterine surgery or myomectomy (excluding hysteroscopic myomectomy)\n* Allergy to misoprostol and lactose\n* Patients with hypersensitivity to misoprostol and\u002For other prostaglandins or to any of the product's excipients.\n* Patients taking aspirin or anti-coagulants\n* Patients with haemostasis disorders\n* Malnourished patients\n* Patients with hepatic or renal insufficiency\n* Pregnancy, suspected ectopic pregnancy and breast-feeding women.\n* Minors\n* Guardianship, curatorship, deprived of liberty, safeguard of justice","18 Years","43 Years",{"count":56,"type":19},80,[22],"In France, uterine fibroids or leiomyomas are the most common benign tumour in women of childbearing age.\n\nIn 30% of cases, fibroids are symptomatic (menorrhagia, anaemia, pain), in which case surgical management is indicated. This is known as myomectomy, and can be performed by hysteroscopy, laparoscopy (laparoscopy) or laparotomy, depending on the number, size and position of the fibroids.\n\nIntraoperative bleeding is the main surgical difficulty. For this reason, a number of studies have focused on ways of minimizing the risk of bleeding.\n\nA good surgical indication, prevention of anaemia (iron deficiency) and transient occlusion of the uterine arteries during surgery help to reduce this risk. There are also drugs available to reduce intraoperative bleeding, but few studies have been carried out to assess their real effectiveness. One such product is Misoprostol, commonly used in gynecology. Its muscle-contracting properties suggest that it could have a beneficial effect on bleeding during surgery. What's more, this treatment has been used for many years and is reputed to be very well tolerated. The most frequent side effects are digestive, with a risk of abdominal pain in the form of cramps, nausea or vomiting.\n\nThe investigators therefore decided to set up the HEMOMYOC study to demonstrate a significant reduction in bleeding during laparotomy or laparoscopic myomectomy after taking oral misoprostol in combination with transient occlusion of the uterine arteries, compared with placebo. It would seem that the ease of use and good tolerance of misoprostol, in combination with transient occlusion of the uterine arteries, could be of real benefit in preventing intraoperative morbidity in myomectomies, whatever the surgical approach. To date, no studies have been carried out in this area.",[60,27],"Myoma;Uterus",[62,63,64],"myomectomy","surgical blood loss","misoprostol","2025-09-19",{"date":67,"type":38},"2025-09-24",{"date":69,"type":38},"2025-03-12",{"date":71,"type":19},"2028-04-17",{"name":73,"class":45},"University Hospital, Clermont-Ferrand",1]